Filing Flows › Comparisons › CRVO vs BDPT
CervoMed vs Bioadaptives: CRVO and BDPT compared
CervoMed is the larger company: $9K of revenue in its latest quarter (Q4 2025) against $5K for Bioadaptives (Q2 2026). Bioadaptives is growing faster (+55% against -100% a year earlier).
Where the money goes: CRVO and BDPT
CervoMed (CRVO) · Q4 2025
CervoMed, Q4 2025: revenue $9K (-100% year over year), net loss $8.1M, operating cash flow −$6.6M. The chart follows the revenue to costs, profit and cash.
Bioadaptives (BDPT) · Q2 2026
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart follows the revenue to costs, profit and cash.
| CervoMed (CRVO) | Bioadaptives (BDPT) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $9K | $5K |
| Revenue growth, Y/Y | -100% | +55% |
| Operating margin | n/m | n/m |
| Net earnings | −$8.1M | $150K |
| Operating cash flow | −$6.6M | −$44K |
Questions
Which is bigger, CervoMed or Bioadaptives?
CervoMed is the larger company: $9K of revenue in its latest quarter (Q4 2025) against $5K for Bioadaptives (Q2 2026).
Is CervoMed or Bioadaptives growing faster?
Bioadaptives is growing faster (+55% against -100% a year earlier).
More: CervoMed earnings · how CervoMed makes money · Bioadaptives earnings · how Bioadaptives makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 13, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.